TJBio and MorphoSys announce that TJ210/MOR210 has been approved by the FDA for clinical trials

TJ210/MOR210 is a highly differentiated monoclonal antibody for complement factor C5a subject 1 (C5aR1).
tumor tissue can form a tumor micro-environment that inhibits T-cell function by producing C5a, recruiting immunosuppressive cells such as myelin-based inhibitory cells (MDSCs), M2 macrophages, and neutrinotic granulocytes that are C5A-positive.
TJ210/MOR210 is designed to block the interaction of C5a and C5aR1 by binding to C5aR1, thus delaying the migration of immunosuppressive cells.
preclinical studies have shown strong anti-tumor activity by linking them to immuno-checkpoint inhibitors.
November 2018, MorphoSys signed an exclusive strategic partnership and regional licensing agreement with Tiantian Bio for TJ210/MOR210.
the terms of the agreement, Tiantian Bio has exclusive rights to develop and commercialize TJ210/MOR210 in Greater China and Korea, while MorphoSys reserves rights in other parts of the world.
also supported by MorphoSys, Tiansa will also be responsible for clinical trials and proof-of-concept trials of TJ210/MOR210 for cancer diseases worldwide, including in the United States and China.
, the two companies are also working together on MorphoSys' self-developed human-source CD38 monoclonal antibody TJ202/MOR202.
Heavenly Creatures has exclusive development and commercial rights in Chinese mainland, Taiwan, Hong Kong and Macau, and has conducted two registered clinical studies in 2019 to assess the efficacy and safety of its treatment for patients with relapsed or resuscable multiple myeloma.
.